SEQENS North America Wins Big at 2019 Life Science Leader Magazine CMO Leadership Awards

Wins “Top Performer” in 12 categories

NEWBURYPORT, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/APIs?src=hash" target="_blank"gt;#APIslt;/agt;–SEQENS North America (formerly PCI Synthesis, Inc.), a pharmaceutical
manufacturer of new chemical entities (NCEs), generic active
pharmaceutical ingredients (APIs), and other specialty chemical
products, announced that it has won six additional 2019 Life
Science Leader CMO Leadership Awards that were handed out at the
awards dinner held during DCAT Week in New York City.

In addition to awards for Quality, Capabilities, Compatibility,
Expertise, Reliability, and Service across all three groups of
respondents Big Pharma, Small Pharma and Overall (combined Big and Small
Pharma), SEQENS also was recognized for its work across the following
Specialty Award categories: Accessible Senior Management, Innovation,
Reputation, Right First Time, State-of-the-Art and Strength of Science.

The Specialty Awards categories were established because Life
Science Leader readers referred to these attributes as being the
most important “intangibles” to the industry.

In total, the company won 12 awards this year for a total of 36 starting
from 2013, when the CMO Leadership Awards were first presented. For the
2019 CMO Leadership Awards, Life Science Leader magazine
teamed up with Industry Standard Research (ISR) to determine the award
recipients. More than 120 contract manufacturers were assessed by 23
performance metrics in ISR’s annual Contract Manufacturing
Quality Benchmarking survey.

“Over the years, we’ve found that the intangibles are important to our
sponsors. We pay particular attention to making sure our senior
management team is accessible to each and every sponsor. The way we
operate, a sponsor’s size doesn’t matter. Whether big or small, whether
a single molecule startup or a multinational with a deep drug
development pipeline, all drug developers want their project to be a
priority. Meeting timelines is critically important, as it impacts costs
and initiation of planned clinical trials,” said Ed Price, president and
CEO of SEQENS North America. “Winning all these awards validates our
approach, our people, training and equipment, and continues to be
gratifying to see that being recognized by the industry.”

About SEQENS North America
SEQENS North America (formerly
PCI Synthesis) is a Pharmaceutical Development CDMO (Contract
Development and Manufacturing Organization) based in Newburyport, Mass.,
a division of SEQENS, an integrated global leader in pharmaceutical
synthesis and specialty ingredients with 24 manufacturing sites and 3
R&D centers in Europe, North America and Asia.

SEQENS North America is also a commercial manufacturer of new chemical
entities (NCEs), generic active pharmaceutical ingredients (APIs), and
other specialty chemical products for the medical device industry. As a
CDMO, SEQENS North America provides emerging and mid-sized
pharmaceutical companies access to the expertise needed to develop and
manufacture complex small molecules. To learn more about SEQENS North
America, its proprietary NCE development activities and process R&D
capabilities please visit www.seqens.com.

Contacts

Linda Pendergast-Savage
Birnbach Communications
508-224-7905
[email protected]